These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 27266406)

  • 21. When should pelvic sentinel lymph nodes be harvested in patients with malignant melanoma?
    Kaoutzanis C; Barabás A; Allan R; Hussain M; Powell B
    J Plast Reconstr Aesthet Surg; 2012 Jan; 65(1):85-90. PubMed ID: 21940229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The intriguing effect of delay time to sentinel lymph node biopsy on survival: a propensity score matching study on a cohort of melanoma patients.
    Tejera-Vaquerizo A; Descalzo-Gallego MA; Traves V; Requena C; Bolumar I; Pla A; Nagore E
    Eur J Dermatol; 2017 Oct; 27(5):487-495. PubMed ID: 28944755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Prognostic Markers in Stage IIIB Melanoma.
    Madu MF; Wouters MW; Klop WM; van der Hiel B; van de Wiel BA; Jóźwiak K; van der Hage JA; van Akkooi AC
    Ann Surg Oncol; 2016 Dec; 23(13):4195-4202. PubMed ID: 27380642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma.
    Wagner JD; Gordon MS; Chuang TY; Coleman JJ; Hayes JT; Jung SH; Love C
    Cancer; 2000 Jul; 89(2):453-62. PubMed ID: 10918179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of sentinel lymph node biopsy on survival for intermediate-thickness melanoma.
    Kachare SD; Brinkley J; Wong JH; Vohra NA; Zervos EE; Fitzgerald TL
    Ann Surg Oncol; 2014 Oct; 21(11):3377-85. PubMed ID: 25063010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience.
    Fairbairn NG; Orfaniotis G; Butterworth M
    J Plast Reconstr Aesthet Surg; 2012 Oct; 65(10):1396-402. PubMed ID: 22552263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique.
    Rutkowski P; Szydłowski K; Nowecki ZI; Sałamacha M; Goryń T; Mitręga-Korab B; Pieńkowski A; Dziewirski W; Zdzienicki M
    World J Surg Oncol; 2015 Oct; 13():299. PubMed ID: 26462471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sentinel node biopsy as a prognostic factor in cutaneous melanoma].
    Avilés-Izquierdo JA; Lázaro-Ochaita P
    Actas Dermosifiliogr; 2009; 100(6):486-92. PubMed ID: 19709553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sentinel node biopsy in malignant melanoma: Swedish experiences 1997-2005.
    Mattsson J; Bergkvist L; Abdiu A; Aili Low JF; Naredi P; Ullberg K; Garpered U; Håkansson A; Ingvar C
    Acta Oncol; 2008; 47(8):1519-25. PubMed ID: 18941953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of intra-nodal naevi in sentinel node biopsies for malignant melanoma.
    Smith OJ; Coelho JA; Trevatt AE; Ross GL
    Eur J Surg Oncol; 2016 Sep; 42(9):1427-31. PubMed ID: 27262872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
    Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
    Nowecki ZI; Rutkowski P; Michej W
    Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sentinel node biopsy (SNB) in malignant melanoma as same day procedure vs delayed procedure: clinical and economic outcome.
    Rødgaard JC; Kramer S; Stolle LB
    J Plast Surg Hand Surg; 2014 Aug; 48(4):265-9. PubMed ID: 24328901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sentinel-node biopsy or nodal observation in melanoma.
    Morton DL; Thompson JF; Cochran AJ; Mozzillo N; Elashoff R; Essner R; Nieweg OE; Roses DF; Hoekstra HJ; Karakousis CP; Reintgen DS; Coventry BJ; Glass EC; Wang HJ;
    N Engl J Med; 2006 Sep; 355(13):1307-17. PubMed ID: 17005948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma.
    Koskivuo I; Hernberg M; Vihinen P; Virolainen S; Talve L; Seppänen M; Vahlberg T; Jahkola T
    Br J Surg; 2011 Oct; 98(10):1400-7. PubMed ID: 21638276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma.
    Scheri RP; Essner R; Turner RR; Ye X; Morton DL
    Ann Surg Oncol; 2007 Oct; 14(10):2861-6. PubMed ID: 17882497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden.
    Satzger I; Leiter U; Gräger N; Keim U; Garbe C; Gutzmer R
    Eur J Cancer; 2019 Dec; 123():83-91. PubMed ID: 31677550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sentinel node biopsy in thin and thick melanoma.
    Mozzillo N; Pennacchioli E; Gandini S; Caracò C; Crispo A; Botti G; Lastoria S; Barberis M; Verrecchia F; Testori A
    Ann Surg Oncol; 2013 Aug; 20(8):2780-6. PubMed ID: 23720068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.
    Leiter U; Stadler R; Mauch C; Hohenberger W; Brockmeyer N; Berking C; Sunderkötter C; Kaatz M; Schulte KW; Lehmann P; Vogt T; Ulrich J; Herbst R; Gehring W; Simon JC; Keim U; Martus P; Garbe C;
    Lancet Oncol; 2016 Jun; 17(6):757-767. PubMed ID: 27161539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.